Study guide
6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
DABT: Diplomate of the American Board of Toxicology Exam
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Study Design Fundamentals
1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration
2 Dose Selection, Controls & Biostatistics in Toxicology
2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data
3 Study Execution, GLP Compliance & Quality Assurance
3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections
4 Executing In Vivo, In Vitro, In Silico & Field Studies
4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization
5 Clinical Pathology & Toxicologic Pathology
5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation
6 Specialized Toxicological Study Endpoints
6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
7 Toxicokinetics & Biotransformation
7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
8 Cellular Mechanisms of Toxicity & Organ Pathogenesis
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity
9 Hazard Identification & Evidence Integration
9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses
10 Mode of Action, AOPs & Non-Cancer Endpoints
10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects
11 Exposure Assessment Methodologies & Quantification
11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF
12 Quantitative Dose-Response Principles & Point of Departure Derivation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose
13 Health-Based Guidance Value Derivation & Uncertainty Factors
13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
14 Risk Characterization for Non-Cancer & Cancer Health Effects
14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization
15 Risk Management, Occupational Exposure Limits & Environmental Standards
15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations
16 Regulatory Frameworks & Product Stewardship
16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH
17 Clinical Toxicology & Medical Management of Poisoning
17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies
18 Environmental, Ecological & Public Health Toxicology
18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
Key Takeaways Explain This Topic AI
ICH S7A core battery tests vital functions: cardiovascular (blood pressure, heart rate, ECG), central nervous system (motor activity, behavior, coordination, reflexes, temperature; FOB or Irwin), and respiratory (rate plus tidal volume or oxygen saturation—cage-side watching is not enough).
ICH S7B adds an in vitro IKr/hERG assay and an in vivo QT assay; those studies, when submitted, should be GLP and can share animals with the S7A cardiovascular core study.
ICH S8 starts from standard toxicity-study immune signals (hematology, lymphoid weights and histology, globulins); intended immunomodulators and unresolved signals lead to function tests such as TDAR, immunophenotyping, and host resistance.
Skin sensitization uses LLNA (OECD 429) or defined approaches (OECD 497); phototoxicity screening uses OECD 432 3T3 NRU when the molecule absorbs relevant light; local tolerance covers the clinical route.
Add follow-up or supplemental studies when the core battery, class, structure, route, or intended pharmacology creates a specific concern—not as a default second animal species for every small molecule.
Last updated: September 2026
Why these add-on packages are exam content
A clean 28-day histopathology package can still miss an acute QT-prolonging ion-channel effect, a ventilatory drive problem, or an antibody-response defect that only appears after immunization. Domain I.C asks you when those specialized studies are part of the core package and when they are follow-up . ExamFinch independent study material covers ICH S7A , S7B , S8 , and the OECD methods used for sensitization and phototoxicity. It is not an ABT, ICH, or OECD product and does not claim official approval or partnership.
ICH S7A core battery
The core battery investigates vital functions : cardiovascular, respiratory, and central nervous systems. Exclude a limb of the battery only with a scientific justification (for example some locally applied agents with negligible systemic exposure). Core studies intended for regulatory submission are conducted to GLP . Timing is before first-in-human dosing for typical small molecules ( ICH M3(R2) ). Biotechnology-derived products follow ICH S6(R1) principles; a full small-molecule S7B hERG panel is often not informative for large proteins that never touch IKr.
Cardiovascular: measure blood pressure, heart rate, and electrocardiogram . Conscious telemetry in dog, minipig, or nonhuman primate is common. In vitro or ex vivo work on repolarization is considered alongside, and is developed fully in S7B.
Central nervous system: assess motor activity, behavioral changes, coordination, sensory/motor reflexes, and body temperature . A functional observation battery (FOB) or modified Irwin test in rodents is the usual core. This is not a substitute for a full developmental neurotoxicity cohort, and it is not a street-drug abuse-liability package.
Respiratory: quantify respiratory rate and another function measure such as tidal volume or hemoglobin oxygen saturation . Clinical observation of animals is generally not adequate. A technician noting “no dyspnea” in a dog telemetry room has not met S7A respiratory expectations. Whole-body or head-out plethysmography in rodents is a typical dedicated design.
Doses should include and exceed the therapeutic range up to, but not past, doses that wreck the pharmacologic readout (profound sedation that prevents ECG interpretation is not a useful high dose). Use the clinical route when feasible.
ICH S7B: hERG and QT
S7B complements S7A for delayed ventricular repolarization . The most common pharmaceutical mechanism of QT prolongation is block of IKr , whose pore-forming subunit is encoded by hERG (KCNH2) . The nonclinical package is:
In vitro IKr assay (cloned hERG or native IKr).
In vivo QT assay (conscious animals preferred; heart-rate correction must be justified).
The in vivo QT study can be designed to satisfy both S7A cardiovascular core and S7B, reducing animal use. Follow-up (other ion channels, action-potential duration, in vivo arrhythmia models) is triggered by mixed signals, chemical class, or inability to interpret hERG because of solubility or cytotoxicity. Clinical ECG strategy ( ICH E14 ) is interpreted with this nonclinical integrated risk assessment; a huge hERG IC50 margin with a clean in vivo QT is not the same story as a low-nanomolar hERG blocker with QTc prolongation in dogs.
Supplemental safety pharmacology
S7A supplemental studies cover systems that are not acutely vital in the core sense but become important because of findings, class, or patient population : renal function, gastrointestinal motility and secretion, autonomic nervous system, and deeper CNS (learning/memory, seizure threshold, drug-dependence). Run them when the core battery, secondary pharmacology, or the intended population raises a specific question—not as a checklist second species.
Immunotoxicology (ICH S8)
S8 starts with a weight-of-evidence review of standard toxicity studies (STS) : leukocyte counts and differentials, globulins, lymphoid organ weights, and histopathology of spleen, thymus, lymph nodes, and mucosa-associated lymphoid tissue. Additional immunotoxicity testing is called for when STS changes suggest immunosuppression or unintended immunostimulation, when the compound is an intended immunomodulator , or when patient populations (already immunocompromised) raise concern.
If extra work is needed, an immune function study is recommended, typically a T-cell dependent antibody response (TDAR) to sheep red blood cells or keyhole limpet hemocyanin (KLH) without adjuvant (alum only with justification, generally in nonhuman primates). Immunophenotyping (flow cytometry of leukocyte subsets) is a non-functional adjunct that can identify affected populations and sometimes a clinical biomarker. Host-resistance models (for example Listeria , influenza, or tumor challenge) are used when the clinical infection-risk question is still open after TDAR. Natural-killer activity, macrophage function, cytotoxic T-lymphocyte assays, and delayed-type hypersensitivity are selected when STS points at those cell types. Intended immunosuppressants are not “cleared” by a quiet 28-day lymphoid histology; function testing is expected.
Sensitization, phototoxicity, and local tolerance
Skin sensitization. The murine local lymph node assay (LLNA, OECD 429) measures lymphocyte proliferation in draining nodes (classically 3H-thymidine). A stimulation index of ≥3 is the traditional positive threshold; EC3 estimates potency. Non-radioactive LLNA variants exist ( OECD 442A/442B ). OECD 497 defined approaches combine in chemico and in vitro key-event tests ( OECD 442C peptide binding, 442D keratinocyte activation, 442E dendritic-cell activation) so many chemicals can be classified without a new in vivo LLNA. Guinea-pig maximization and Buehler tests ( OECD 406 ) remain historical. Dermal products, reactive impurities, and workplace chemicals drive this work more often than a standard oral small-molecule IND.
Phototoxicity. If the molecule absorbs in the 290–700 nm range and reaches light-exposed tissues (skin, eyes), screen with OECD 432 (3T3 Neutral Red Uptake, ±UVA). Interpretation uses photo-irritation factor (PIF) and/or mean photo effect (MPE) ; ICH S10 describes the pharmaceutical phototoxicity strategy, including when an in vivo or clinical phototest follows a positive 3T3. A colorless molecule with no absorbance is not a 432 candidate.
Local tolerance. For non-oral clinical routes (intravenous, subcutaneous, intramuscular, dermal, ocular), evaluate irritation at the administration site. This can be a standalone local-tolerance study or, preferably, endpoints built into general toxicity using the clinical formulation and route. Do not assume an oral 28-day rat study covers an intravenous clinical product’s infusion-site risk.
When to add these to a general toxicology package
- Add-on Default for a systemic small-molecule IND? Typical trigger to add or expand
- S7A core (CV, CNS, respiratory) Yes, before first-in-human Always unless justified exclusion
- S7B hERG/QT Yes for new chemical entities Class effect, mixed nonclinical/clinical ECG signals
- Supplemental S7A (renal, GI, abuse, seizure) No Core findings, secondary pharmacology, patient population
Extra S8 function tests No, unless STS or intended immuno Cytotoxic/immunosuppressive pharmacology; STS lymphoid changes
- LLNA / OECD 497 No for most oral drugs Dermal exposure, reactive chemistry, classification needs
- OECD 432 / S10 No Light absorbance plus relevant tissue exposure
- Local tolerance If clinical route is not already used in general tox Parenteral, dermal, or ocular products
- Realistic scenario
A first-in-human oral kinase inhibitor has S7A telemetry (blood pressure, heart rate, ECG) in dogs, a rodent Irwin test, and rodent plethysmography, plus hERG and in vivo QT. Repeat-dose rats show thymic atrophy and a drop in T-cell counts. The package is incomplete if the sponsor files only “no infections were seen in rats.” S8 wants a TDAR (and likely immunophenotyping) because STS already flagged the lymphocyte lineage. LLNA and 3T3 phototoxicity remain unnecessary if the molecule is oral, not dermally applied, and does not absorb UVA/UVB. A supplemental GI motility study would be follow-up if vomiting and delayed gastric emptying appeared in dogs, not a core-battery requirement on day one.
Traps
Counting cage-side “normal respiration” as the S7A respiratory study.
Treating hERG IC50 in isolation without in vivo QT and free-concentration margins.
Skipping TDAR for an intended immunosuppressant because histology looked tidy.
Running LLNA on every oral small molecule “for completeness.”
Assuming an oral general-tox study covers intravenous local tolerance.